Use-case guide

AI in Pharmaceuticals & Drug Discovery

Pharma AI splits into three regulatory tracks: (1) AI for early-stage drug discovery (relatively light-touch — IP and trade-secret framing dominates), (2) AI in clinical trial design and patient stratification (FDA/EMA guidance is becoming binding fast), and (3) AI in pharmacovigilance and adverse-event reporting (where the rules are oldest and strictest). The big shift in 2024-2025 is that FDA's CDER and CBER both issued draft guidance treating AI used in drug-submission components as a regulated activity — meaning the model itself becomes part of the submission package.

For: Pharma R&D leaders, clinical-ops VPs, biotech founders using AI for discovery, regulatory affairs (FDA/EMA), AI-drug-discovery vendors

What's at stake

FDA AI/ML in drug development guidance is binding-in-practice

FDA's 2023 'Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products' discussion paper, plus the 2024 follow-on draft guidance, treats AI as a regulated submission component. Models used in dosing decisions, biomarker discovery, or clinical trial enrolment must be documented in the IND/NDA/BLA.

EMA Reflection Paper on AI in medicines lifecycle (2023)

EMA's 2023 reflection paper establishes risk-based AI oversight across medicine lifecycle. The EU AI Act overlays this for any AI that's also a medical device (SaMD).

Pharmacovigilance AI has strict adverse-event-detection duties

Using AI in AE signal detection requires documented validation, audit trail, and 24-hour serious-AE reporting. EMA and FDA both have inspection authority over the pipeline; a missed serious AE traceable to AI failure is a regulatory finding.

AI-discovered molecules raise IP and inventorship questions

Thaler v. Vidal (Fed. Cir. 2022) established that AI cannot be a named inventor under US patent law. EPO, UKIPO, and most major patent offices have similar positions. Companies must document the human contribution to inventorship — the AI-tool framing is not optional.

Regulations that apply

FDA AI/ML draft guidance for drug development

Guideline
→

AI models used in submissions are part of the regulatory record. Documentation, validation, performance monitoring, and change-control plans expected.

Where in the text: FDA Discussion Paper (2023); FDA Draft Guidance (2024) on AI for Drugs.

EMA Reflection Paper on AI in medicines

Guideline
→

Risk-based framework across the medicines lifecycle. Higher scrutiny for AI affecting benefit-risk assessment or labelling.

Where in the text: EMA/CHMP/389777/2023 — Reflection Paper on AI in the Lifecycle of Medicines.

EU AI Act (where AI is also a medical device)

Law
→

AI software classified as a medical device (under MDR/IVDR) is high-risk under Article 6(1) + Annex I. Conformity assessment integrates AI Act with MDR.

Where in the text: Article 6(1); Annex I; MDR Regulation (EU) 2017/745.

ICH GCP / E6(R3) + Good Pharmacovigilance Practices

Law
→

Clinical trial AI must satisfy ICH GCP integrity requirements. Pharmacovigilance AI sits under EMA GVP Module IX and FDA FAERS expectations.

Where in the text: ICH E6(R3); EMA GVP Module IX; 21 C.F.R. Part 314.80.

Do

  • ✓Maintain a 'model registry' that catalogues every AI used anywhere in the regulatory submission lifecycle, with version, training data, validation report, and human-oversight policy.
  • ✓Build a change-control plan for any AI affecting submission content — both FDA and EMA expect a Predetermined Change Control Plan (PCCP)-style submission.
  • ✓Document human-inventor contribution to AI-assisted IP. The 'human conception' standard is the threshold for patentability — document the human cognitive contribution explicitly.
  • ✓For AI in clinical-trial patient stratification: bias-test on historically-underrepresented populations and publish the methodology in the trial protocol.
  • ✓Treat AI-generated text in your submission (e.g. literature reviews, drafted briefing documents) as requiring the same accuracy-and-citation discipline as human-written content.

Don't

  • ✗Don't omit AI used in your submission from the regulatory record — FDA Form 1572 disclosures + IND amendments will need to reflect AI involvement going forward.
  • ✗Don't use uncurated public-data-trained foundation models for pharmacovigilance signal detection without revalidating on your own pharmacovigilance database.
  • ✗Don't run an AI-driven clinical decision-support feature into a US healthcare partner without confirming FDA SaMD classification — many AI features cross the medical-device line.
  • ✗Don't ignore IP-licence implications when using open-weight models on proprietary chemical libraries — the licence chain may infect your patent estate.
  • ✗Don't claim 'AI discovered this drug' in regulatory or investor communications when the AI was a tool — the FTC and SEC have been clear that this overclaim invites enforcement.

Also worth knowing

If you're using generative AI for medical writing in submissions: ICH E3 and FDA's CDER guidance on the structure of clinical study reports apply — submissions can't be opaque about authorship. For AI-discovered new chemical entities: the US PTO's 2024 inventorship guidance requires human-conception documentation; preserve lab notebooks, sketches, and the human chemist's reasoning trail.

Want a tailored answer?

The wizard takes your jurisdiction, AI use case, and data types and gives you the top-3 regulations to focus on — in 60 seconds.

Start the wizard →

Educational guide. Not legal advice. For specific compliance decisions, consult qualified counsel in the relevant jurisdiction.

Note: this guide was drafted with AI assistance — Anthropic Claude.